Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Gomollón, F.; Dignass, A.; Annese, V.; Tilg, H.; Van Assche, G.; Lindsay, J.O.; Peyrin-Biroulet, L.; Cullen, G.J.; Daperno, M.; Kucharzik, T.; et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J. Crohn’s Colitis 2017, 11, 3–25. [Google Scholar] [CrossRef] [PubMed]
- Harbord, M.; Eliakim, R.; Bettenworth, D.; Karmiris, K.; Katsanos, K.; Kopylov, U.; Kucharzik, T.; Molnar, T.; Raine, T.; Sebastian, S.; et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J. Crohn’s Colitis 2017, 11, 769–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chouchana, L.; Narjoz, C.; Beaune, P.; Loriot, M.A.; Roblin, X. Review article: The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012, 35, 15–36. [Google Scholar] [CrossRef] [PubMed]
- Marinaki, A.M.; Ansari, A.; Duley, J.A.; Arenas, M.; Sumi, S.; Lewis, C.M.; Shobowale-Bakre, E.M.; Escuredo, E.; Fairbanks, L.D.; Sanderson, J.D. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14, 181–187. [Google Scholar] [CrossRef] [PubMed]
- Cuffari, C.; Theoret, Y.; Latour, S.; Seidman, G. 6-Mercaptopurine metabolism in Crohn’s disease: Correlation with efficacy and toxicity. Gut 1996, 39, 401–406. [Google Scholar] [CrossRef] [PubMed]
- De Nicolò, A.; Agnesod, D.; Simiele, M.; Riganò, D.; Adriani, A.; Canaparo, R.; Astegiano, M.; Rizzetto, M.; Di Perri, G.; D’Avolio, A. UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. J. Pharm. Biomed. Anal. 2014, 98, 271–278. [Google Scholar] [CrossRef] [PubMed]
- Weinshilboum, R.M.; Sladek, S.L. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980, 32, 651–662. [Google Scholar] [PubMed]
- Otterness, D.; Szumlanski, C.; Lennard, L.; Klemetsdal, B.; Aarbakke, J.; Iven, H.; Schmiegelow, K.; Branum, E.; O’Brien, J.; Weinshilboum, R.; et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin. Pharmacol. Ther. 1997, 62, 60–73. [Google Scholar] [CrossRef]
- Loennechen, T.; Utsi, E.; Hartz, I.; Lysaa, R.; Kildalsen, H.; Aarbakke, J. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin. Pharmacol. Ther. 2001, 70, 183–188. [Google Scholar] [CrossRef]
- Summary of Product Characteristics. 2011. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034s035lbl.pdf (accessed on 25 November 2017).
- Magro, F.; Gionchetti, P.; Eliakim, R.; Ardizzone, S.; Armuzzi, A.; Acosta, M.B.D.; Burisch, J.; Gecse, K.B.; Hart, A.L.; Hindryckx, P.; et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J. Crohn’s Colitis 2017, 11, 649–670. [Google Scholar] [CrossRef]
- Greenberg, J.A.; Hsu, J.; Bawazeer, M.; Marshall, J.; Friedrich, J.O.; Nathens, A.; Coburn, N.; May, G.R.; Pearsall, E.; McLeod, R.S. Clinical practice guideline: Management of acute pancreatitis. Can. J. Surg. 2016, 59, 128–140. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, L.A.; Collins-Yoder, A.; Collins, R.E. Drug-Induced Liver Injury. AACN Adv. Crit. Care 2016, 27, 430–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moon, W.; Loftus, E.V. Review article: Recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2016, 43, 863–883. [Google Scholar] [CrossRef] [PubMed]
- Actis, G.C.; Pellicano, R.; Ribaldone, D.G. A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms. Rev. Recent Clin. Trials 2019, 14, 4–9. [Google Scholar] [CrossRef] [PubMed]
- Coenen, M.J.; De Jong, D.J.; Van Marrewijk, C.J.; Derijks, L.J.; Vermeulen, S.H.; Wong, D.R.; Klungel, O.H.; Verbeek, A.L.; Hooymans, P.M.; Peters, W.H.; et al. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology 2015, 149, 907–917. [Google Scholar] [CrossRef]
- Collie-Duguid, E.S.; Pritchard, S.C.; Powrie, R.H.; Sludden, J.; Collier, D.A.; Li, T.; McLeod, H.L. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9, 37–42. [Google Scholar] [CrossRef] [PubMed]
- Present, D.H.; Meltzer, S.J.; Krumholz, M.P.; Wolke, A.; Korelitz, B.I. 6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity. Ann. Intern. Med. 1989, 111, 641–649. [Google Scholar] [CrossRef]
- Dubinsky, M.C.; Lamothe, S.; Yang, H.Y.; Targan, S.R.; Sinnett, D.; Théoret, Y.; Seidman, E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118, 705–713. [Google Scholar] [CrossRef]
- Haber, C.J.; Meltzer, S.J.; Present, D.H.; Korelitz, B.I. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986, 91, 982–986. [Google Scholar] [CrossRef]
- Liu, Y.P.; Xu, H.Q.; Li, M.; Yang, X.; Yu, S.; Fu, W.L.; Huang, Q. Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis. PLoS ONE 2015, 10, e0144234. [Google Scholar] [CrossRef]
- Coelho, T.; Andreoletti, G.; Ashton, J.J.; Batra, A.; Afzal, N.A.; Gao, Y.; Williams, A.P.; Beattie, R.M.; Ennis, S. Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Sci. Rep. 2016, 6, 34658. [Google Scholar] [CrossRef] [PubMed] [Green Version]
UC Patients | CD Patients | |
Sex, n (%) | ||
Males | 48 (60) | 68 (57) |
Females | 32 (40) | 52 (43) |
Age at diagnosis (mean age, range) | 33 (13–59) | 30.5 (16–67) |
Azathioprine therapy n (%) | ||
Ongoing | 56 (70) | 84 (70) |
Stopped for adverse events | 24 (30) | 36 (30) |
Average time azathioprine is ongoing (months) | 69 | 59 |
Adverse Event, n (% among Patients who have Stopped Azathioprine Therapy due to Toxicity) | TPMT Genotype (Number of Patients) |
---|---|
Pancreatitis, 28 (47) | *1/*1 (26) |
*1/*3A (2) | |
Hepatitis, 24 (40) | *1/*1 (24) |
Leukopenia, 6 (10) | *1/*1 (6) |
Nausea and vomiting, 2 (3) | *1/*1 (2) |
Overall Toxicity 1 | Pancreatitis 2 | Gender 3 | Disease 4 | |||||
---|---|---|---|---|---|---|---|---|
Yes | No | Yes | No | Males | Females | CD | UC | |
Mutated | 2 | 6 | 2 | 6 | 4 | 4 | 2 | 6 |
Wild-Type | 58 | 134 | 26 | 166 | 112 | 80 | 118 | 74 |
Total | 60 | 140 | 28 | 172 | 116 | 84 | 120 | 80 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ribaldone, D.G.; Adriani, A.; Caviglia, G.P.; De Nicolò, A.; Agnesod, D.; Simiele, M.; Riganò, D.; Pellicano, R.; Canaparo, R.; Di Perri, G.; et al. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina 2019, 55, 441. https://doi.org/10.3390/medicina55080441
Ribaldone DG, Adriani A, Caviglia GP, De Nicolò A, Agnesod D, Simiele M, Riganò D, Pellicano R, Canaparo R, Di Perri G, et al. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina. 2019; 55(8):441. https://doi.org/10.3390/medicina55080441
Chicago/Turabian StyleRibaldone, Davide Giuseppe, Alessandro Adriani, Gian Paolo Caviglia, Amedeo De Nicolò, Danilo Agnesod, Marco Simiele, Danila Riganò, Rinaldo Pellicano, Roberto Canaparo, Giovanni Di Perri, and et al. 2019. "Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients" Medicina 55, no. 8: 441. https://doi.org/10.3390/medicina55080441